

What Every Intensivist should Know about Impairment of Cardiac Function and Arrhythmias in Liver Disease Patients: A Review

Sanjeev Arya¹, Prashant Kumar², Bhuwan Tiwari³, Shantanu Belwal⁴, Sanjay Saxena⁵, Haider Abbas⁶

ABSTRACT

Objectives: Impairment of cardiac function and arrhythmias often coexist in patients with liver diseases. Many studies have proved this coexistence and put forward various theories toward its pathophysiology. This narrative review tries to find the answers with supporting evidence on five main questions:

- Do high serum bilirubin levels have a strong association with cardiac arrhythmias?
- Can corrected QT interval (QTc) be relied upon for predicting a risk factor toward imminent arrhythmias?
- Is there an association between QTc prolongation and mortality?
- Are high serum bilirubin and cardiac dysfunction closely associated?
- What is the probable pathophysiology behind this association?

Materials and methods: Clinical evidence was obtained by using search engines, namely, Cochrane Library, PubMed, and Google Scholar. Studies published in journals in the English language, between January 1969 and December 2019, which mentioned the relationship between cardiac arrhythmia and liver disease, were included. We used the keywords: jaundice, bilirubin, arrhythmia, ECG, QTc interval, QT dispersion, liver, and cirrhosis. Relevant animal or human studies answering the five main questions were extracted and reviewed.

Conclusion: The evidence included in our review sheds light on the fact that approximately 50% of liver cirrhosis cases develop cirrhotic cardiomyopathy (CC) and there has been an association between liver abnormalities and cardiac pathology. The present review also supports that there exists a strong association between high levels of serum bilirubin levels and cardiac arrhythmias, QTc value can be relied upon as a risk factor for predicting imminent arrhythmias, and that it is associated with mortality. Its basic pathophysiology can be explained by the potential action of bile acids in prolonging the QT interval. It also causes cardiac hypertrophy and apoptosis of cardiomyocytes leading to cardiac dysfunction.

Keywords: Arrhythmia, Bilirubin, Bradycardia, Cirrhosis, Corrected QT interval, Dysrhythmias, ECG, Jaundice, Levels, Liver, QT dispersion, QT interval, Serum.

Indian Journal of Critical Care Medicine (2020): 10.5005/jp-journals-10071-23695

INTRODUCTION

Liver disease rates are steadily increasing over the years. According to National statistics in the UK, liver diseases have been ranked as the fifth most common cause of death. Liver diseases are recognized as the second leading cause of mortality among all digestive diseases in the US.^{1,2} The global prevalence of cirrhosis falls in the range between 4.5 and 9.5% of the general population. It was estimated that more than 50 million people in the world suffer from chronic liver disease.^{3,4} Deaths from cirrhosis are constantly increasing and it would make it the 12th leading cause of death in 2020.⁵

Cardiac arrhythmias are frequently seen in patients with jaundice, especially in cases with “acute decompensation of chronic liver disease”, frequently admitted to intensive care units. Mostly these are new-onset arrhythmias, and they pose a real challenge to the intensivists in understanding their pathophysiology and hence managing them. They are often resistant to treatment and tend to recur. It has been estimated that these arrhythmias are associated with 200% higher mortality, longer hospital stay, and therefore higher expenditure on medical management. It is also associated with higher rates of shock, respiratory, and kidney failures. Due to this reason, it is suggested that a robust system needs to be evolved toward screening and follow-ups of end-stage liver disease (ESLD) patients for dysrhythmias.^{6,7}

¹Department of Critical Care, Max Super Specialty Hospital (Previously), Dehradun, India

²Department of Critical Care, Kailash Hospital, Noida, Uttar Pradesh, India

³Department of Cardiology, Ram Manohar Lohia Institute of Medical Sciences, Vibhuti Khand, Gomti Nagar, Lucknow, Uttar Pradesh, India

^{4,5}Department of Critical Care, Max Super Specialty Hospital, Dehradun, India

⁶Department of ER and Critical Care, King Georges Medical University, Lucknow, Uttar Pradesh, India

Corresponding Author: Sanjeev Arya, Department of Critical Care, Max Super Specialty Hospital (Previously), Dehradun, India, Phone: +91135 7193000, e-mail: sanjeev.arya@hotmail.co.uk

How to cite this article: Arya S, Kumar P, Tiwari B, Belwal S, Saxena S, Abbas H. What Every Intensivist should Know about Impairment of Cardiac Function and Arrhythmias in Liver Disease Patients: A Review. *Indian J Crit Care Med* 2020;24(12):1251–1255.

Source of support: Nil

Conflict of interest: None

In this narrative review, we aim to find and agree upon a reliable parameter that can predict impending cardiac arrhythmias

which if found can be acted upon promptly and hence would prevent a significant amount of morbidity and mortality. We have summarized evidence that supports the relationship between high serum bilirubin levels and cardiac arrhythmias. A detailed literature search was also done to explain the pathophysiology behind this phenomenon. Therefore, the objective is set to find answers with supporting evidence on five main questions:

- Do high serum bilirubin levels have a strong association with cardiac arrhythmias?
- Can corrected QT interval (QTc) be relied upon for predicting a risk factor toward imminent arrhythmias?
- Is there an association between QTc prolongation and mortality?
- Are high serum bilirubin and cardiac dysfunction, closely associated?
- What is the probable pathophysiology behind this association?

MATERIALS AND METHODS

Data Sources and Search Strategy

We used the Cochrane Library, Google Scholar, and PubMed to search for the eligible studies. English language studies which were published in journals during the years 1969–2019, addressing the relationship between cardiac arrhythmia and liver dysfunction. We used the keywords: jaundice, bilirubin, arrhythmia, ECG, QTc interval, QT dispersion, liver, and cirrhosis. Letters to editor, conference papers, book reviews, book chapters, newspaper, expert opinions, and theses or dissertations were not used. We excluded the articles that were not published in the English language. Relevant studies answering the five main questions were extracted.

Titles were screened first, then abstracts, based on inclusion and exclusion criteria. Questionable eligibility based on title and abstract was read in full and judged for eligibility. Duplicates were eliminated and irrelevant articles were excluded from the review. The references of all articles, selected for full-text evaluation, were reviewed for the potentially eligible studies.

DISCUSSION

The functioning of the liver and the heart interact mutually. Often liver induced cardiac disease goes underdiagnosed due to its complex pathophysiology. The present review was conducted to find evidence regarding this interaction with the help of five questions. The very first question raised in our review is whether cardiac arrhythmias have a strong association with serum bilirubin levels or not. We found that there is a significant coexistence between the functioning of the liver and heart, a liver disease affecting the heart, and *vice versa*.⁸ The heart is the most affected organ in the patient with liver cirrhosis and the frequent cardiac symptoms experienced with liver failure are palpitations, dyspnea, angina chest discomfort, electrocardiographic changes, tachycardia, and bradycardia.⁹

The risk of arrhythmia is influenced by factors, such as, cirrhotic cardiomyopathy (CC), cardiac-ion-channel remodeling, impaired autonomic functions, impaired electrolyte balance, hepatorenal syndrome, and impaired drug metabolism, which advocates closed monitoring of cirrhotic patients.¹⁰ In the mid-70s, a study demonstrated a high incidence of cardiac arrhythmias in patients with fulminant hepatic failure. A high number of these patients suffered from heart block and developed bradycardia. A quarter of these patients had sudden cardiac death. More than a quarter of the

total number of patients enrolled showed T wave and ST-segment changes, out of which, only 10% of patients who had arrhythmias survived. Almost 50% of the patients who died of arrhythmias did not show any macroscopic changes in the heart on autopsy. Therefore, this study strongly advocated close cardiac monitoring in acute hepatic failure cases.¹¹

Nakasone et al.¹² and Yamamoto and Friedman¹³ in their case report found that Torsade de Pointes, a rare, life-threatening arrhythmia, is associated with alcoholic liver cirrhosis and CC, respectively. Even peripheral autonomic neuropathy which is often seen in cirrhotic patients can cause arrhythmias.¹⁴

Yet, another study done in the late 70s found that 35% of patients with alcoholic liver disease showed PR prolongation and intraventricular conduction defect was seen in 50%.¹⁵ A study done in recent years showed a high incidence and prevalence of atrial fibrillation in patients with liver disease. It also showed that the magnitude of liver disease, as estimated by model end-stage liver disease (MELD), is a good predictor for new-onset atrial fibrillation.¹⁶

The second question was to find out whether QTc can be relied upon as a risk factor or for predicting imminent arrhythmias. A few studies have demonstrated that there exists a strong association between high bilirubin levels and QTc. Corrected QT interval refers to the length of ventricular electric inactivity during cardiac repolarization, its prolongation increases chances of impairment of the cardiac function and ventricular arrhythmias.¹⁷ Reddy and Boddu showed that QTc was significantly higher in patients with liver cirrhosis who were admitted to special care units.¹⁸ Earlier a study done by Kempler demonstrated that patients with primary biliary cirrhosis had remarkable prolongation of the QTc.¹⁹

Prolongation of QT interval is multifactorial caused by acquired conditions like electrolyte imbalance, alcohol toxicity, coronary disease, an autonomic imbalance with sympathetic factor hyperactivity, and vagal neuropathy.^{20,21} QT, QTc, and their dispersions were significantly longer ($p < 0.01$) in patients with cirrhosis than in controls.²² QT prolongation was common in liver cirrhosis²³ and ESLD.^{24,25} Corrected QT interval prolongation is correlated not only with the severity of the cirrhosis but also with some of the most severe complications of liver disease, such as, hepatorenal syndrome and hepatic encephalopathy.²⁶ Additionally, the Child-Pugh score which depicts the severity of cirrhosis is statistically related to QTc duration.²⁷ Yet, another study found that sudden cardiac deaths due to QTc prolongation in patients prepared for liver transplant result in significant loss of resources.²⁸

Since we have got sufficient evidence that QTc can be used as a reliable risk factor for eminent arrhythmias, we now need to find that “is there a strong association between QTc prolongation and mortality?”. Few previous studies by Mahmud et al.,²⁹ Liang et al.,³⁰ and Bernal and Wendon³¹ demonstrated that acute or acute-on-chronic liver disease is associated with high short- and long-term mortalities. The commonest cause of death among patients admitted to the hospitals was liver failure (24%).³² Most of the patients with “well-compensated cirrhosis” do not require hospital admission and they stay at home. This group of patients, in particular, is at high risk of having sudden cardiac death. This could be prevented if QTc values are recorded and managed promptly by starting empirical anti-arrhythmic medications and by keeping such patients under close monitoring.^{33,34}

A prolonged QT interval is associated with an increased risk of sudden death due to arrhythmias.^{35–37} According to various studies, after in-hospital cardiopulmonary resuscitation (CPR),

the outcomes are usually poor in patients with ESLD and even worse than patients with metastatic cancer, sudden death is also considered an important feature of CC.^{38,39}

Corrected QT interval prolongation is commonly found in patients with ESLD and it is a significant independent predictor of mortality (OR = 1.69, $p = 0.039$).⁴⁰ Prolonged QTc (>440 ms) is associated with increased mortality ($p < 0.05$) in liver cirrhosis and therefore, QT-prolonging drugs must be prescribed cautiously in such patients.⁴¹ But a study done by Bal and Thuluvath found conflicting results with the studies mentioned above. They showed that prolonged QTc interval was common in patients with cirrhosis, but its presence had no independent effect on mortality.⁴²

Many studies explored the probable pathophysiology behind dysrhythmias in jaundiced patients. In this review article, we have also tried to find the answer to this question. Experiments conducted in humans and animals with cirrhotic liver disease have shown marked hemodynamic changes. In the heart, basal contractility, responsiveness to β -adrenoceptor activation, and excitation-contraction coupling (ECC) are negatively affected in models of cirrhosis and portal hypertension with portosystemic shunting (PVS) and these events comprise the CC. It was realized that the reason behind these events may be the increased levels of circulating levels of bile acids.

Zavec and Battarbee investigated the action of bile acids in rats which were anesthetized, and then cirrhosis was induced. They found that the bile acids act as a toxicant to myocardial cells, as demonstrated by exposing cardiac muscle *in vitro* to bile acids impair the cardiac, in addition to that, there was a depressed β -adrenoceptor-mediated inotropism and decreased calcium entry during the depolarization phase. These findings suggest that lipophilic bile acids have a potential role in the myocardial consequences of chronic portal vein stenosis and carbon-tetra chloride (CCl₄) induced cirrhosis.⁴³

Binah et al. studied the effects of bile acids on ventricular muscle and electrophysiological properties, they found that all types of bile acids (primary, conjugated, and secondary) in the plasma of patients with cholestatic jaundice showed a negative inotropic effect. Bile acids caused a reduction in the duration of the ventricular action potential, but resting potential, action potential amplitude, and maximum upstroke velocity of phase 0 depolarization remain unaffected.⁴⁴ Gazawi et al. in a study on in rat cardiac membrane demonstrated the effects of deoxycholic acid (DCA), chenodeoxycholic acid (C-DCA), and their taurine conjugates, namely T-DCA and T-CDCA, on the binding features of β -adrenoceptors, membrane fluidity, and the extent of lipid peroxidation. They proposed that bile acid is a causative factor for the cardiomyopathy of cholestatic liver disease as they cause negative inotropism and chronotropism and attenuate cardiac responsiveness to sympathetic stimulation. They also modify membrane fluidity and generate reactive oxygen species (ROS).⁴⁵

The role of β -adrenoceptor signal transduction in the pathophysiology of CC was studied by Ma et al. in a rat model of cirrhosis. They found that it is the contractile element of the heart that is impaired in cirrhosis, associated with altered β -adrenergic receptor signaling function and guanine nucleotide-binding protein expression.⁴⁶ The relationship between bile acid metabolism and cardiac dysfunction has been determined with both *in vitro* systems and experimental models in intact animals.

Direct effects of bile acid exposure can be observed *in vitro* using isolated cardiomyocytes and muscle strips. The indirect effect of bile metabolism can also be determined through animal models of cirrhosis which are known to result in CC.⁴⁷ Ferreira et al. conducted a study to test a hypothesis that bile acids are toxic to heart mitochondria for concentrations that are relevant for cholestasis. The mitochondria of heart cells were isolated from the rat and subjected to incubation with selected bile acids. The authors concluded that the bile acids alter mitochondrial bioenergetics and cause impairment of mitochondrial function. This may be an important cause for the observed cardiac dysfunction during cholestasis.⁴⁸

Torregrosa et al. found that patients with cirrhosis had higher left ventricular wall thickness ($p < 0.05$) and ejection fraction ($p < 0.001$) than controls.⁴⁹ Bogin et al., in their experiment, studied the effect of jaundiced serum and bile salts on the beating heart cells. The jaundiced serum which was collected from the common bile duct ligated rats were added to cultured heart cells. It was seen that the beating rate of the cultured heart cells decreased, with early cessation of beating occurred, associated with the production of higher levels of lactate in the media. These findings suggest that patients with liver failure produce deoxycholate which is the main toxic substance responsible for altering heart function.⁵⁰ Vasavana et al. in their study demonstrated that an elevation of serum bile acid concentration is associated with impaired cardiac function, the formation of CC.⁵¹

The last question raised in our review article was whether high serum bilirubin is associated with cardiac dysfunction. It has been estimated that almost half of all cases of liver cirrhosis result in the development of CC, which shows systolic and diastolic dysfunction, changes in the electrophysiology of the heart.⁵² Chronic liver disease is frequently associated with cardiovascular complications, such as, tachycardia, myocardial infarction, and congestive heart failure as shown in retrospective studies conducted by Matsumori et al. and Baratta et al.^{53,54}

Ward et al. conducted a study in a rat model, with induced cirrhosis, to explore the underlying mechanisms for the electrophysiological abnormalities that develop as a consequence of cirrhosis of the liver.⁵⁵ Various review articles also proved that liver disorders have an association with heart abnormalities.^{56,57} A study designed to assess the cardiac involvement in jaundiced patients found a significantly reduced response to intravenous dobutamine, as compared to, that seen in the normal controls. It suggests that such myocardial refractoriness to β -1 stimulation makes jaundiced patients more susceptible to postoperative shock and multiorgan failure.⁵⁸

Ward et al. in their study concluded that cardiac contractility is depressed in cirrhotic patients due to malfunction of the Ca^{2+} -regulatory system.⁵⁹

On the contrary, Demir et al.⁶⁰ conducted a study among 102 patients with non-valvular chronic atrial fibrillation without any other cardiovascular disease (mean age 62.51 ± 5.88) and found that total, direct, and indirect serum bilirubin levels were significantly lower among persons with atrial fibrillation when compared with controls ($p < 0.001$), respectively. They concluded that an inverse relationship exists between serum bilirubin and non-valvular atrial fibrillation. Similarly, Cüre et al.⁶¹ in their observational study found that Gilbert syndrome patients are associated with increased bilirubin levels which consequently might decrease the incidence

of cardiac arrhythmias, suggesting myocardial protection provided by serum bilirubin levels.

CONCLUSION

The evidence included in our review suggested that cardiac arrhythmias are associated with high levels of serum bilirubin levels, QTc is a reliable risk factor for imminent arrhythmias, and it is associated with mortality. Approximately 50% of liver cirrhosis cases develop CC. The basic pathophysiology behind this is the bile acids that cause prolonging the QT interval. They cause cardiac hypertrophy and apoptosis of cardiomyocytes. Also, a high level of serum bilirubin is associated with cardiac dysfunction. These observations directly suggest that there has been an association between liver abnormalities and cardiac pathology.

FUTURE PERSPECTIVE

We have tried our best to depict the relationship between the pathologies of liver and heart and the probable mechanism behind this association through the evidence present in the literature but further randomized controlled studies are needed to establish the causality between these two.

AUTHOR'S CONTRIBUTION

Conceptualization is done by—Sanjeev Arya, Haider Abbas, Sanjay Saxena, and Shantanu Belwal. Data curation—Sanjeev Arya and Shantanu Belwal. Formal analysis—Sanjeev Arya, Sanjay Saxena, and Prashant Kumar. Methodology—Sanjeev Arya, Prashant Kumar, Haider Abbas and Bhuwan Tiwari. Resources—Sanjeev Arya, Sanjay Saxena, and Bhuwan Tiwari. Supervision—Sanjeev Arya, Prashant Kumar, and Shantanu Belwal. Writing (original draft)—Sanjeev Arya. Writing (review and editing)—Sanjeev Arya, Prashant Kumar, and Bhuwan Tiwari, Haider Abbas.

ACKNOWLEDGMENTS

Humble gratitude to Dr A K Singh (Medical advisor) for providing resources and constant encouragement toward this review article's completion. Special thanks to Maj. Rahul Prashad (Medical Superintendent) and Dr Ravikant Gupta (Medical Director), Dr Puneet Tyagi (Deputy Medical Director), Max Super Specialty Hospital, Dehradun, for their advice on manuscript preparation, guidance, and valuable inputs.

REFERENCES

1. UK national statistics. Available at: <http://www.statistics.gov.uk/>. Accessed on August 2019.
2. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. *Gastroenterol* 2009;136(4):1134–1144. DOI: 10.1053/j.gastro.2009.02.038.
3. Melato M, Sasso F, Zanconati F. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies. *ZentralblPathol* 1993;139:25–30.
4. Gaudal N, Leth P, Marbjerg L, Galloe AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. *J Intern Med* 1991;230(2):165–171. DOI: 10.1111/j.1365-2796.1991.tb00425.x.
5. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. *Clin Liver Dis* 2008;12(4):733–746. DOI: 10.1016/j.cld.2008.07.007.

6. Bashour T, Antonini C, Fisher J. Severe sinus node dysfunction in obstructive jaundice. *Ann Intern Med* 1985;103(3):384–385. DOI: 10.7326/0003-4819-103-3-384.
7. Song E, Segal I, Hodkinson J, Kew MC. Sinus bradycardia in obstructive jaundice--correlation with total serum bile acid concentrations. *S Afr Med J* 1983;64(14):548–551.
8. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. *J Clin Invest* 1953;32(10):1025–1033. DOI: 10.1172/JCI102813.
9. Hayashi J, Kashiwagi S, Okeda T, Okamura H, Ishibashi H, Hiramatsu Y, et al. Electrocardiographic changes related to hypersecretion of catecholamine in a patient with fulminant hepatitis. *Jpn J Med* 1988;27(2):187–190. DOI: 10.2169/internalmedicine1962.27.187.
10. Mozos I. Arrhythmia risk in liver cirrhosis. *World J Hepatol* 2015;7(4):662–672. DOI: 10.4254/wjh.v7.i4.66.
11. Weston MJ, Talbot IC, Horoworth PJ, Mant AK, Capildeo R, Williams R, et al. Frequency of arrhythmias and other cardiac abnormalities in fulminant hepatic failure. *BMJ Heart* 1976;38(11):1179–1188. DOI: 10.1136/hrt.38.11.1179.
12. Nakasone H, Sugama R, Sakugawa H, Matayoshi R, Miyagi T, Maeshiro T, et al. Alcoholic liver cirrhosis complicated with torsade de pointes during plasma exchange and hemodiafiltration. *J Gastroenterol* 2001;36(8):564. DOI: <https://doi.org/10.1007/s005350170061>.
13. Yamamoto T, Friedman SE. Torsades de pointes in severe alcohol withdrawal and cirrhosis: implications for risk stratification and management. *Fed Pract* 2017;34(1):38–41.
14. Fleckenstein JF, Frank SM, Thuluvath PJ. Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. *Hepatology* 1996;23(3):471–475. DOI: 10.1002/hep.510230311.
15. Luca C. Electrophysiological properties of right heart and atrioventricular conducting system in patients with alcoholic cardiomyopathy. *Br Heart J* 1979;42(3):274–281. DOI: 10.1136/hrt.42.3.274.
16. Huang WA, Dunipace EA, Sorg JM, Vaseghi M. Liver disease as a predictor of new-onset atrial fibrillation. *J Am Heart Assoc* 2018;7(15):e008703. DOI: 10.1161/JAHA.118.008703.
17. Enar S, Özkan AA, Pehlivanoğlu S, Enar R. The relationship between QT dispersion and left and right ventricular diastolic dysfunction in patients with myocardial infarction. *Anadolu Kardiyol Derg* 2001;1:266–271.
18. Reddy VCS, Boddu J. A study of changes in QTc interval in ECG in cirrhosis of liver. *J Evolut Med Dent Sci* 2015;4(102):16759–16760. DOI: 10.14260/jemds/2015/2510.
19. Kempler P. Autonomic and peripheral neuropathy in primary biliary cirrhosis: evidence of small sensory fiber damage and prolongation of the QT interval. *J Hepatol* 1994;21(6):1150–1151. DOI: 10.1016/S0168-8278(05)80640-3.
20. Bernardi M, Trevisani F, De Palma R, Ligabue A, Capani F, Baraldini M, et al. Chronobiological evaluation of sympatho-adrenergic function in cirrhosis. *Relation Arter Press Heart Rate Gastroente* 1987;93:1178–1186.
21. Green J, Beyar R, Sideman S, Mordechovitz D, Better OS. The "jaundiced heart": a possible explanation for postoperative shock in obstructive jaundice. *Surgery* 1986;5:14–19.
22. Tsiompanidis E, Siakavellas SI, Tentolouris A, Eleftheriadou I, Chorepsima S, Manolakis A, et al. Liver cirrhosis-effect on QT interval and cardiac autonomic nervous system activity. *World J Gastrointest Pathophysiol* 2018;9(1):28–36. DOI: 10.4291/wjgp.v9.i1.28.
23. Zhao J, Qi X, Hou F, Ning Z, Zhang X, Deng H, et al. Prevalence, risk factors and in-hospital outcomes of QTc interval prolongation in liver cirrhosis. *Am J Med Sci* 2016;352(3):285–295. DOI: 10.1016/j.amjms.2016.06.012.
24. Patel D, Singh P, Katz W, Hughes C, Chopra K, Nemej J. QT interval prolongation in end-stage liver disease cannot be explained by non-hepatic factors. *Ann Non-Invas Electrocardiol* 2004;19(6):574–581. DOI: 10.1111/anec.12161.

25. Rehman M, Taneja P, Gurnaney H. New-onset prolonged QTc leading to Torsade de pointes in a child with acute liver disease. *Pediatric Anesthesia* 2012;22(6):593–595. DOI: 10.1111/j.1460-9592.2012.03862.x.
26. Scarlatescu E, Tomescu D, Droc G, Manga G. Is prolonged QTc interval associated with the severity and complications of liver cirrhosis? *Eur J Anesthesiol* 2013;30:197. DOI: 10.1097/00003643-201306001-00616.
27. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. *Hepatology* 1998;27(1):28–34. DOI: 10.1002/hep.510270106.
28. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. *Hepatology* 1996;23(5):1128–1134. DOI: 10.1002/hep.510230529.
29. Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Incidence and mortality of acute-on-chronic liver failure using two definitions in patients with compensated cirrhosis. *Hepatology* 2019(5). DOI: 10.1002/hep.30494.
30. Liang R, Liu A, Perumpail RB, Wong RJ, Ahmed A. Advances in alcoholic liver disease: an update on alcoholic hepatitis. *World J Gastroenterol* 2015;21(42):11893–11903. DOI: 10.3748/wjg.v21.i42.11893.
31. Bernal W, Wendon J. Acute liver failure. *N Engl J Med* 2013;369(26):2525–2534. DOI: 10.1056/NEJMra1208937.
32. Schlichting P, Christensen E, Fauerholdt L, Poulsen H, Juhl E, Tygstrup N. Main causes of death in cirrhosis. *Scand J Gastroenterol* 1983;18(7):881–888. DOI: 10.3109/00365528309182110.
33. Dănulescu RM, Stanciu C, Trifan A. Evaluation of prognostic factors in decompensated liver cirrhosis with ascites and spontaneous bacterial peritonitis. *Rev Med Chir Soc Med Nat Iasi* 2015;119(4): 1018–1024.
34. Orman ES, Roberts A, Ghahril M, Nephew L, Desai AP, Patidar K, et al. Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis. *JAMA Netw Open* 2019;2(6):e196412. DOI: 10.1001/jamanetworkopen.2019.6412.
35. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. *Lancet* 1993;341(8858):1423–1428. DOI: 10.1016/0140-6736(93)90879-L.
36. Kupari M, Koskinen P. Alcohol, cardiac arrhythmias and sudden death. *Novartis Found Symp* 1998;216:68–79.
37. Moushmouth B, Abi-Mansour P. Alcohol and the heart. The long-term effects of alcohol on the cardiovascular system. *Arch Intern Med* 1991;151(1):36–42. DOI: 10.1001/archinte.151.1.36.
38. Ufere NN, Brahmania M, Sey M, Teriaky A, El-Jawahri A, Walley KR, et al. Outcomes of in-hospital cardiopulmonary resuscitation for patients with end-stage liver disease. *Liver Int* 2019;39(7):1256–1262. DOI: 10.1111/liv.14079.
39. Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? *Expert Rev Gastroenterol Hepatol* 2012;6(1):57–66. DOI: 10.1586/egh.11.86.
40. Kim SM, George B, Alcivar-Franco D, Campbell CL, Charnigo R, Delisle B, et al. QT prolongation is associated with increased mortality in end stage liver disease. *World J Cardiol* 2017;9(4):347–354. DOI: 10.4330/wjc.v9.i4.347.
41. Adigun AQ, Chmasani NP, Murray P, Farmd MD, Ho H, Hall SD. QTc prolongation as a risk factor for mortality in liver cirrhosis. *Clin Pharmacol Ther* 2003;73(2):P119. DOI: 10.1016/S0009-9236(03) 90480-2.
42. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. *Liver Int* 2003;23(4):243–248. DOI: 10.1034/j.1600-0676.2003.00833.x.
43. Zavec JH, Battarbee HD. The role of lipophilic bile acids in the development of cirrhotic cardiomyopathy. *Cardiovasc Toxicol* 2010;10(2):117–129. DOI: 10.1007/s12012-010-9069-8.
44. Binah O, Rubinstein I, Bomzon A, Better OS. Effects of bile acids on ventricular muscle contraction and electrophysiological properties: studies in rat papillary muscle and isolated ventricular myocytes. *Naunyn-Schmiedeberg's Arch Pharmacol* 1987;335(2):160–165. DOI: 10.1007/BF00177718.
45. Gazawi H, Ljubuncic P, Cogan U, Hochgraff E, Ben-Shachar D, Bomzon A. The effects of bile acids on β -adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. *Biochem Pharmacol* 2000;59(12):1623–1628. DOI: 10.1016/S0006-2952(00)00259-8.
46. Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. *Gastroenterol* 1996;110(4):1191–1198. DOI: 10.1053/gast.1996.v110. pm8613009.
47. Desai MS, Shabier Z, Taylor M, Lam F, Thevananther S, Kosters A, et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. *Hepatology* 2010;51(6):2097–2107. DOI: 10.1002/hep.23585.
48. Ferreira M, Coxito PM, Sardão VA, Palmeira CM, Oliveira PJ. Bile acids are toxic for isolated cardiac mitochondria. *Cardiovasc Toxicol* 2005;5:63–73. DOI: 10.1385/CT:5:1:063.
49. Torregrosa M, Aguadé S, Dos L, Segura R, González A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. *J Hepatol* 2005;42(1):68–74. DOI: 10.1016/j.jhep.2004.09.008.
50. Bogin E, Better O, Harari I. The effect of jaundiced sera and bile salts on cultured beating heart cells. *Experientia* 1983;39(11):1307–1308. DOI: 10.1007/BF01990384.
51. Vasavana T, Ferrarob E, Ibrahim E, Dixona P, Gorelikb J, Williamsona C. Heart and bile acids – clinical consequences of altered bile acid metabolism. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1864;4:1345–1355. DOI: 10.1016/j.bbadis.2017.12.039.
52. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassel BW, et al. Cirrhotic cardiomyopathy. *J Am Coll Cardiol* 2010;56(7):539–549. DOI: 10.1016/j.jacc.2009.12.075.
53. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. *Circulation* 1995;92(9):2519–2525. DOI: 10.1161/01.CIR.92.9.2519.
54. Baratta L, Tubani L, Merli M, Labbadia F, Facchini D, De Marco R, et al. Long-term effect of liver transplantation on cirrhotic autonomic cardiac dysfunction. *Dig Liver Dis* 2010;42(2):131–136. DOI: 10.1016/j.dld.2009.05.009.
55. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. *Am J Physiol* 1997;273(2):G537–G544. DOI: 10.1152/ajpgi.1997.273.2.G537.
56. Møller S, Dümcke CW, Krag A. The heart and the liver. *Expert Rev Gastroente Hepatol* 2009;3(1):51–64. DOI: 10.1586/17474124.3.1.51.
57. Fouad YM, Yehia R. Hepato-cardiac disorders. *World J Hepatol* 2014;6(1):41–54. DOI: 10.4254/wjh.v6.i1.41.
58. Lumlertgul D, Boonyaprapa S, Bunnachak D, Thanachaikun N, Praisontarangkul O, Phornphutkul K, et al. The jaundiced heart: evidence of blunted response to positive inotropic stimulation. *renal failure*. 1991;13(1):15–22. DOI: 10.3109/08860229109022141.
59. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. *Gastroenterol* 2001;1219(5):1209–1218. DOI: 10.1053/gast.2001.28653.
60. Demir M, Demirc B, Uyana U, Meleka M. The relationship between serum bilirubin concentration and atrial fibrillation. *Cardiol Res* 2013;4(6):186–191. DOI: 10.4021/cr299w.
61. Cüre E, Yüce S, Çiçek Y, Cüre MC. The effect of Gilbert's syndrome on the dispersions of QT interval and P-wave: an observational study. *Anadolu Kardiyol Derg* 2013;13:559–565.